Vinayak Doraiswamy Sells 6,000 Shares of AtriCure (NASDAQ:ATRC) Stock

AtriCure, Inc. (NASDAQ:ATRC) insider Vinayak Doraiswamy sold 6,000 shares of the business’s stock in a transaction on Tuesday, July 28th. The stock was sold at an average price of $38.88, for a total transaction of $233,280.00. Following the completion of the sale, the insider owned 86,511 shares in the company, valued at $3,363,547.68. This represents a 6.49% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link.

AtriCure Price Performance

AtriCure stock opened at $37.76 on Friday. AtriCure, Inc. has a 52-week low of $25.36 and a 52-week high of $43.18. The company has a quick ratio of 3.18, a current ratio of 4.22 and a debt-to-equity ratio of 0.14. The firm’s fifty day moving average is $31.10 and its 200 day moving average is $31.34. The company has a market cap of $1.92 billion, a price-to-earnings ratio of 179.82 and a beta of 1.24.

AtriCure (NASDAQ:ATRC) last issued its quarterly earnings data on Thursday, July 23rd. The medical device company reported $0.18 EPS for the quarter. AtriCure had a net margin of 1.85% and a return on equity of 2.34%. The business had revenue of $153.60 million during the quarter, compared to analysts’ expectations of $151.80 million. During the same period last year, the company posted ($0.13) EPS. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. Sell-side analysts forecast that AtriCure, Inc. will post 0.2 EPS for the current fiscal year.

Analyst Ratings Changes

ATRC has been the topic of several analyst reports. UBS Group reduced their price objective on AtriCure from $55.00 to $50.00 and set a “buy” rating on the stock in a research note on Tuesday. Canaccord Genuity Group raised their price objective on AtriCure from $53.00 to $55.00 and gave the company a “buy” rating in a research note on Wednesday, May 6th. Weiss Ratings raised AtriCure from a “sell (e+)” rating to a “sell (d+)” rating in a research note on Tuesday. Citigroup reiterated a “market outperform” rating on shares of AtriCure in a report on Tuesday, July 21st. Finally, Wall Street Zen downgraded AtriCure from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 2nd. Two research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $48.50.

Institutional Investors Weigh In On AtriCure

Several institutional investors have recently made changes to their positions in the company. Geneos Wealth Management Inc. purchased a new position in shares of AtriCure during the 2nd quarter worth about $37,000. Harbor Investment Advisory LLC purchased a new stake in AtriCure in the 2nd quarter worth about $40,000. Smartleaf Asset Management LLC lifted its stake in AtriCure by 59.8% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,146 shares of the medical device company’s stock worth $46,000 after purchasing an additional 429 shares during the last quarter. Fifth Third Bancorp purchased a new position in shares of AtriCure during the first quarter valued at approximately $51,000. Finally, Global Retirement Partners LLC purchased a new position in shares of AtriCure during the fourth quarter valued at approximately $73,000. Institutional investors own 99.11% of the company’s stock.

AtriCure News Roundup

Here are the key news stories impacting AtriCure this week:

• Positive Sentiment: AtriCure’s recent second-quarter results exceeded expectations, with earnings per share of $0.18 versus the $0.13 analyst estimate and revenue of $153.6 million versus $151.8 million expected. The company also improved from a year-ago loss, supporting its growth and profitability outlook. AtriCure second-quarter results presentation
• Positive Sentiment: UBS lowered its price target from $55 to $50 but retained a Buy rating. The revised target still indicates meaningful potential upside and suggests the analyst remains constructive on AtriCure’s medical-device business. UBS AtriCure price target report
• Neutral Sentiment: Options-market coverage points to the possibility of a significant upcoming move in ATRC, but the available information does not establish whether traders are positioning for a rise or decline. Elevated options activity could contribute to short-term volatility. AtriCure options activity article
• Neutral Sentiment: New share-registration filings may give AtriCure additional financing flexibility. However, investors may monitor the filings for potential future share issuance and dilution. AtriCure share registration article
• Negative Sentiment: Insiders sold approximately $1.42 million of AtriCure shares. Director Sven Wehrwein reduced his position by about 38%, while insiders Justin J. Noznesky and Vinayak Doraiswamy each sold roughly 6% of their holdings. The clustered selling may weigh on sentiment, particularly after ATRC’s strong advance toward its 52-week high. AtriCure insider selling report

About AtriCure

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.